Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Mega Genomics Limited ( (HK:6667) ).
Mega Genomics Limited reported solid financial growth for the year ended 31 December 2024, with operating revenue rising 8.5% year-on-year to RMB164.2 million and net profit jumping 50.0% to RMB45.0 million. Management attributed the improved performance to continued product design innovation, an expanded and optimized product mix, and a proactive market expansion strategy that diversified sales channels and enhanced customer experience. Consumer genetic testing services were the main growth driver, with revenue in this segment surging 47.3% to RMB159.6 million, while revenue from cancer screening services declined sharply by 89.2% to RMB4.6 million, indicating a strategic or market shift in the business mix. Overall gross profit rose 35.2% to RMB119.3 million, lifting gross margin from 58.4% to 72.7%, and net profit margin improved from 19.9% to 27.4%, underscoring increased operational efficiency and a stronger profitability profile as the company consolidates its leadership position in China’s consumer genetic testing market.
More about Mega Genomics Limited
Mega Genomics Limited is a leading genetic testing platform company in China, specializing in consumer genetic testing services and ancillary offerings, as well as cancer screening services. The group operates a large-scale testing network that has completed over 23 million genetic tests and covers healthcare institutions in more than 340 cities nationwide, supplemented by partnerships with e-commerce and online healthcare platforms to broaden its market reach.
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.61B
Find detailed analytics on 6667 stock on TipRanks’ Stock Analysis page.